Gossamer Bio
Agent47Agent Readiness: 47/100. Above median. Measured by StartupHub.ai. Median 41.Trust88Data Trust: 88/100. Top 25%. Measured by StartupHub.ai. Median 61.A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.
About
Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing its investigational drug product, seralutinib, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib is an inhaled inhibitor designed to enhance the lives of people living with these rare diseases. The company is committed to advancing new therapies and supporting patient communities.
Similar companies
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Pharmaceuticals
Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
Shares Biotechnology, Biotech
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Pharmaceuticals
Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.
Shares Biotechnology, Healthcare
Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.
Shares Biotechnology, Drug Discovery
A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
Shares Biotechnology, Pharmaceuticals
Key facts
- Website
- gossamerbio.com
- Headquarters
- San Diego, California, USA
- Founded
- 2017
- Employees
- 154
- Total funding
- $150M (Series B)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 1 Jan 2019 | Series B | $150M | Arch Venture Partners, Deerfield Management |
Tech stack
Detected on gossamerbio.com, last scanned 25 Oct 2026. Run your own scan
- Frontend
- jQuery
- Analytics
- Google Tag Manager
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Email provider
- Microsoft 365
- Video / media
- Vimeo
Gossamer Bio scores 49. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is Gossamer Bio trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Gossamer Bio is 88 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Gossamer Bio raised?
Gossamer Bio has raised a total of $150M in funding. The most recent round on record is Series B.
How many employees does Gossamer Bio have?
Gossamer Bio has approximately 154 people on record.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for Gossamer Bio
